Creative Medical Technology Holdings Announces IRB Approval For FDA Cleared Phase 1/2 Clinical Trial Of StemSpine Using AlloStem Novel Cell Therapy To Treat Chronic Lower Back Pain
Portfolio Pulse from Bill Haddad
Creative Medical Technology Holdings has received IRB approval for an FDA cleared Phase 1/2 clinical trial of StemSpine. The trial will use AlloStem, a novel cell therapy, to treat chronic lower back pain.
October 10, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Creative Medical Technology Holdings' stock may see positive movement following the IRB approval for an FDA cleared Phase 1/2 clinical trial of StemSpine.
The IRB approval for the FDA cleared Phase 1/2 clinical trial of StemSpine is a significant milestone for Creative Medical Technology Holdings. This could potentially lead to positive investor sentiment and an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100